Cost-effectiveness analysis of four sampling and genomic testing strategies for patients with advanced non-small-cell lung cancer in Australia
Pathology · 2026-06 · 58 (4) · 411-419
DOI: 10.1016/j.pathol.2025.12.007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathology, 2026-06. Verfasst von Louisa G Collins und 6 weiteren Autor:innen. Beteiligte Einrichtung: Viertel Cancer Research Centre, Cancer Council Queensland, Brisbane, Qld, Australia; QIMR Berghofer Medical Research Institute, Brisbane, Qld, Austra…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Genetic Testing. Die Arbeit nennt 40 Literaturangaben. Gefördert von: Medical Research Future Fund.
Abstract (Originalsprache)
Molecular testing informs therapy selection for patients with non-small-cell lung cancer (NSCLC) providing access to better treatments. However, the costs and benefits of alternative specimens and testing options are unknown. We modelled the cost-effectiveness of four molecular testing strategies involving combinations of biopsy (tissue aspirate versus liquid), sample (formalin-fixed paraffin-embedded cell block, cytology smears or cell-free DNA) and molecular test (single-gene, small panel or large panel). Outcomes included health system costs, life years and quality-adjusted life years (QALYs) from 5,000 Monte Carlo simulations. One-way and probabilistic sensitivity analyses and budget impact analyses were also undertaken. Over 5 years, the predicted mean costs per person (for combined tissue acquisition, testing and subsequent treatment) ranged from AU$87,915 for standard care to AU$98,712 for cytology smears and large panel sequencing. Outcomes were lowest for single-gene or small gene panel strategies (1.70-1.75 QALYs) and highest for the large-panel strategies (1.82-1.88 QALYs). Compared with standard care, the incremental cost per QALY gained ranged from $59,983 (95% uncertainty interval (UI): AU$48,598, $79,664) to AU$70,840 (95% UI: AU$57,697, AU$87,937). Findings were most sensitive to quality-of-life estimates and targeted therapy costs but not to biopsy, sampling or molecular testing costs. The budget impact of these new diagnostics is not inconsequential with costs up to 64% higher than those for current standard care. For people with advanced NSCLC, alternative sampling and comprehensive genomic testing combinations are potentially cost-effective in Australia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Viertel Cancer Research Centre, Cancer Council Queensland, Brisbane, Qld, Australia; QIMR Berghofer Medical Research Institute, Brisbane, Qld, Australia; Faculty of Health, Medicine and Behavioural Sciences, The Univers…
- School of Biomedical Sciences, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Brisbane, Qld, Australia; UQ Centre for Clinical Research, Faculty of Health, Medicine and Behavioural S…
- Viertel Cancer Research Centre, Cancer Council Queensland, Brisbane, Qld, Australia; QIMR Berghofer Medical Research Institute, Brisbane, Qld, Australia; UQ Centre for Health Services Research, Faculty of Health, Medici…
- Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Brisbane, Qld, Australia.
- Department of Thoracic Medicine, Royal Brisbane and Women's Hospital, Brisbane, Qld, Australia.
- Pathology Queensland, The Royal Brisbane and Women's Hospital, Brisbane, Qld, Australia.
Förderung
- Medical Research Future Fund
Zitieren
APA
Collins, L. G., Simpson, P. T., Lindsay, D., Nones, K., Ryan, K., Fairbairn, D., & Fielding, D. (2026). Cost-effectiveness analysis of four sampling and genomic testing strategies for patients with advanced non-small-cell lung cancer in Australia. Pathology, 58(4), 411-419. https://doi.org/10.1016/j.pathol.2025.12.007
Vancouver
Collins LG, Simpson PT, Lindsay D, Nones K, Ryan K, Fairbairn D, et al. Cost-effectiveness analysis of four sampling and genomic testing strategies for patients with advanced non-small-cell lung cancer in Australia. Pathology. 2026;58(4):411-419. doi:10.1016/j.pathol.2025.12.007
BibTeX
@article{Collins2026,
author = {Collins, Louisa G and Simpson, Peter T and Lindsay, Daniel and Nones, Katia and Ryan, Kimberley and Fairbairn, David and Fielding, David},
title = {Cost-effectiveness analysis of four sampling and genomic testing strategies for patients with advanced non-small-cell lung cancer in Australia},
journal = {Pathology},
year = {2026},
volume = {58},
number = {4},
pages = {411--419},
doi = {10.1016/j.pathol.2025.12.007}
}
EUVIMED